On September 5th, the U.S. FDA granted full approval for our medicine to slow kidney function decline in adults with IgA nephropathy. For more information, see our Press Release.
Search for information about a product, therapeutic area or event
Media, investors, advocacy organizations and others, please contact us here.
For US healthcare professionals only
The purpose of this Travere Therapeutics Medical Affairs website is to support healthcare professionals with scientific information. This website is also a channel for US healthcare professionals to submit questions or connect with Travere Therapeutics US healthcare professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US healthcare professional
Generation of Alagille syndrome derived induced pluripotent stem cell line carrying heterozygous mutation in the JAGGED-1 gene at splicing site(Chr20: 10,629,709C>A) before exon 11
Generation of an induced pluripotent stem cell line (TRNDi031-A) from a patient with Alagille syndrome type 1 carrying a heterozygous p. C312X (c. 936 T > A) mutation in JAGGED-1
Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy
Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)